Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clofarabine: past, present, and future.

Hagop M Kantarjian1, Sima Jeha, Varsha Gandhi

  • 1Department of Leukemia, The University of Texas M. D. Andreson Cancer Center, Houston, Texas 77030, USA. hkantarj@mdanderson.org

Leukemia & Lymphoma
|September 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Cancer·2017
Same author

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Experimental hematology & oncology·2017
Same author

A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.

American journal of hematology·2017
Same author

Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.

Clinical lymphoma, myeloma & leukemia·2017
Same author

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.

Cancer·2017
Same author

US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Blood advances·2017
Same journal

Leukemia mortality analysis in the pediatric population in São Paulo state, Brazil, 2000-2019.

Leukemia & lymphoma·2026
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
See all related articles

Clofarabine, a purine nucleoside analogue, effectively treats pediatric acute lymphoblastic leukemia (ALL) and adult hematologic malignancies like acute myeloid leukemia (AML). Further research explores its use in elderly AML patients and myelodysplastic syndrome (MDS).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Clofarabine is a next-generation purine nucleoside analogue.
  • It combines beneficial properties of cladribine and fludarabine.
  • Its mechanisms include inhibiting ribonucleotide reductase, DNA incorporation, and inducing apoptosis.

Purpose of the Study:

  • To review the efficacy and applications of clofarabine in treating various hematologic malignancies.
  • To highlight its established role in pediatric leukemia and emerging use in adult cancers.

Main Methods:

  • Review of clinical trial data and FDA approvals.
  • Analysis of clofarabine's mechanism of action and synergistic potential with other chemotherapeutics.

Main Results:

Related Experiment Videos

  • Significant efficacy in pediatric relapsed/refractory acute lymphoblastic leukemia (ALL), leading to FDA approval in 2004.
  • Demonstrated efficacy in adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), both as monotherapy and in combination regimens.

Conclusions:

  • Clofarabine is a valuable therapeutic agent for specific pediatric and adult hematologic cancers.
  • Ongoing studies are investigating its utility in elderly AML patients and exploring oral formulations for MDS treatment.